Skip to main content

Advertising Disclaimer »

Main menu

  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • AAP Policy
    • Topic/Program Collections
    • Policy
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effect on Pediatric Health
    • More Collections...
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Alerts
    • Table of Contents
    • Insights
  • AAP Career Center
  • Subscribe
  • Other Publications
    • American Academy of Pediatrics

User menu

  • Log in
  • My Cart

Search

  • Advanced search
American Academy of Pediatrics

AAP Gateway

Advanced Search

AAP Logo

  • Log in
  • My Cart
  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • AAP Policy
    • Topic/Program Collections
    • Policy
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effect on Pediatric Health
    • More Collections...
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Alerts
    • Table of Contents
    • Insights
  • AAP Career Center
  • Subscribe
NEWS AND FEATURES

New infant formula additives approved by FDA

; from the AAP Committee on Nutrition
AAP News May 2002, 20 (5) 209-210;
  • Article
  • Info & Metrics
  • Comments
Loading
Download PDF
  • Copyright © 2002 by the American Academy of Pediatrics
Figure1

Pediatricians should discuss with parents the potential benefits of adding long-chain polyunsaturated fatty acids to formulas for term infants and weigh this information against the increased costs of these new products.

Formulas containing the extra long-chain polyunsaturated fatty acids (LC-PUFAs) are now appearing in hospitals and at formula retail outlets throughout the United States.

Two products currently are available: Enfamil Lipil and Similac Advance with Iron. Both products utilize the same source of LC-PUFAs, which are derived from algae and fungi (Martek Biosciences Corporation). The data pertaining to this source of LC-PUFAs recently were reviewed by the U.S. Food and Drug Administration (FDA) and it was concluded that it probably was safe to add these to term infant formula.

With the wholesale prices for these products approximately 15% higher than standard formulas, this should translate into a higher sticker price at most retail outlets. Currently, no soy-based formulations of these products are available. Also, these new formulas presently are not supplied through the Special Supplemental Nutrition Program for Women, Infants and Children.

LC-PUFAs, by definition, are fatty acids that have chain lengths greater than 18 carbon atoms and contain two or more double bonds. Two such fatty acids are important in infant nutrition — arachidonic acid (ARA or AA) and docosahexonoic acid (DHA). These are present in small concentrations in human milk, but previously were not present in infant formulas.

ARA is derived from the essential fatty acid alpha-linoleic acid, and DHA is derived from the essential fatty acid linolenic acid. Both term and preterm infants can synthesize the LC-PUFAs from the respective essential fatty acids, but controversy has centered around the fact that breastfed infants have higher plasma concentrations of these LC-PUFAs than formula-fed infants. This information could be interpreted to imply that formula-fed infants cannot synthesize enough of these fatty acids to meet ongoing needs, though the plasma content of DHA and ARA is only a very small fraction of the total fatty acid pool available in other tissues.

DHA and ARA are major fatty acids in neural tissue. DHA also is an important component of the photoreceptor of the retina. These fatty acids are supplied to the fetus from maternal plasma during pregnancy, and it is believed that the preterm infant born during the third trimester is at much greater risk for deficiency of these LC-PUFAs than the term infant. It is hypothesized that the addition of DHA to infant formula will improve infant visual function, and that the addition of both DHA and ARA will improve cognitive development. However, to date, the relatively few studies testing these hypotheses have yielded variable results.

Is there any harm to adding DHA or ARA to infant formulas? In approving the addition of these oils to infant formula, the FDA expects infant formula manufacturers to sponsor scientific studies and to pursue rigorous post-marketing surveillance and monitoring of formulas containing DHA and ARA. This recommendation implies that infants may still be at risk for unknown adverse effects of these oils. A negative effect on growth of DHA supplements when provided alone has been reported in preterm infants, but when DHA is combined with ARA as a supplement for formula, no adverse effects on growth have been observed in either term or preterm infants. Concerns have been raised that the addition of LC-PUFAs to formulas for preterm infants will increase the likelihood of oxidant damage, but to date no differences have been reported in the incidence of bronchopulmonary dysplasia, necrotizing enterocolitis or other neonatal conditions in infants receiving supplements of either DHA or both ARA and DHA, compared with unsupplemented formula.

Expert panels from Life Sciences Research Organization assessed nutrient requirements for both term and preterm infant formulas and recommended neither a minimum nor maximum content of either ARA or DHA for term infant formula (Raiten DJ, et al. J Nutr. 1998;128:2059S-2093S). For preterm infant formula, they recommended maximum levels of 0.35% and 0.6% of total fatty acid intake for DHA and ARA, respectively. No minimum levels were recommended (according to a yet-to-be-published study). However, the report concludes that the benefits reported to date for preterm infants are modest and in part transient, thus supporting an optional rather than a mandatory addition of the LC-PUFA to preterm formula.

Given the relative paucity of data on this subject, the AAP Committee on Nutrition (CON) has recommended that the Academy not take an official stand at this time on the addition of LC-PUFAs to term infant formulas. Concerns are raised, however, that the recently introduced formulas are not intended for use in preterm infants, the group most likely to benefit from additional quantities of these fatty acids. (Further FDA approval is necessary for the addition of LC-PUFAs to preterm infant formula.) Though it recently granted approval for the addition of the LC-PUFA oils to infant formula (as noted previously), the FDA has expectations that the formula companies will continue to pursue post-marketing scientific studies and surveillance. As guidelines for such studies of infant formula are nonexistent, and it is yet unclear how the FDA will assure that such studies are completed, CON urges caution regarding the addition of other bioactive factors to formula with similar post-marketing expectations in the future.

What is the bottom line for pediatricians and families? Breast milk still remains the feeding of choice and the availability of these formulas does not change this fact. Pediatricians are urged to discuss with parents what is known about the potential benefits of adding LC-PUFAs to formulas for term infants, while weighing this information against the increased costs of these new products. It should be made clear that at this time these formulas are one of many alternative products available for infants.

PreviousNext
Back to top

Advertising Disclaimer »

In this issue

AAP News
Vol. 20, Issue 5
1 May 2002
  • Table of Contents
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
View this article with LENS
PreviousNext
Email Article

Thank you for your interest in spreading the word on American Academy of Pediatrics.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
New infant formula additives approved by FDA
(Your Name) has sent you a message from American Academy of Pediatrics
(Your Name) thought you would like to see the American Academy of Pediatrics web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Request Permissions
Article Alerts
Log in
You will be redirected to aap.org to login or to create your account.
Or Sign In to Email Alerts with your Email Address
Citation Tools
New infant formula additives approved by FDA
AAP News May 2002, 20 (5) 209-210;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
New infant formula additives approved by FDA
AAP News May 2002, 20 (5) 209-210;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Print
Download PDF
  • Table of Contents

Jump to section

  • Article
  • Info & Metrics
  • Comments

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Strong stance
    AAP releases multiple policies to protect youths from tobacco, nicotine
  • Address causes of climate change to help alleviate effects on children: AAP
  • AAP policy cites harms of e-cigarettes; urges screening
Show more NEWS AND FEATURES

Similar Articles

Subjects

  • Nutrition
    • Nutrition
  • Fetus/Newborn Infant
    • Fetus/Newborn Infant
  • Terms of Use
  • Privacy Statement
  • FAQ
  • Contact Us
  • 2021 AAP Journals Catalog
  • Pediatrics
  • Pediatrics in Review
  • Hospital Pediatrics
  • NeoReviews
  • AAP Grand Rounds
  • AAP Career Center
  • shopAAP
  • AAP.org
  • AAP News
  • Visit AAP News on Facebook
  • Follow AAP News on Twitter
American Academy of Pediatrics

© 2021 American Academy of Pediatrics